non glp-1 weight loss drugs Medications: Everything You Need to Know New GLP-1 weight loss drugs

PMCID: PMC11561716

Each starts at a low dose that can be increased every four weeks as tolerated and needed

In general, the majority of studies suggest that the risk of side effects with DPP-4 inhibitors is equivalent to that of a placebo (inactive pill) [14]

& Ecker, M

A meta-analysis of antioxidant supplementation in individuals with obesity has shown beneficial effects on reducing body mass index (BMI), waist circumference (WC), fasting blood glucose, and improving markers of oxidative stress and inflammation compared to placebo [84]

The dual use of the same medications for diabetes and weight loss introduces operational complexity that did not exist when these drugs were confined to a single indication